

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

- PRI ICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/049,304	03/27/1998	SAVERIO CARL FALCO	BB-1037-F	5349
7590 04/09/2002				
LYNNE M CHRISTENBURY			EXAMINER	
E. I. DU PONT DE NEMOURS AND COMPANY LEGAL - PATENTS 1007 MARKET STREET			MCELWAIN, ELIZABETH F	
			ART UNIT	PAPER NUMBER
WILMINGTO	N, DE 19898		1638	10
			DATE MAILED: 04/09/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summer		09/049,304	FALCO ET AL.				
	Office Action Summary	Examiner	Art Unit				
· · · · · · · · · · · · · · · · · · ·		Elizabeth McElwain	1638				
Period fo	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
1) 🖂	Responsive to communication(s) filed on 12 A	nril 2001					
2a)□		s action is non-final.					
3)	,						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)	6) ☐ Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) <u>1-20</u> are subject to restriction and/or el	ection requirement.					
Application		·					
9) <u></u> ⊤	he specification is objected to by the Examiner.						
	he drawing(s) filed on is/are: a)□ accept	ed or b)□ objected to by the Exam	niner				
	Applicant may not request that any objection to the						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	PTO-413) Paper No(s) tent Application (PTO-152)				

Serial No. 09/049,304 Art Unit 1638

A supplemental restriction requirement was mailed August 29, 2000. Applicants responded with an election on April 12, 2001, and a petition to revive the application, which had unintentionally gone abandonned. Claims 16-20 were previously withdrawn as drawn to a non-elected invention.

Applicant's election of Group I, claims 1-7, 9 and 11-15 in Paper No. 16 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

In addition, applicants submitted a response filed on January 15, 2002, electing 12 SEQ ID Nos for prosecution, stating that the election was in response to an office action mailed on October 22, 2001. However, there is no office action of record in the present application having that date, and no supplemental action has been sent, since the action of August 29, 2000.

In view of the recitation of multiple sequences in the claims, the following supplemental restriction requirement is set forth.

## **Supplemental Restriction**

15

20

10

5

Applicants are reminded that nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute **independent and distinct** inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

In addition to the elected Group I, claims 1-7, 9 and 11-15, Applicant is additionally required to select a single nucleotide sequence and corresponding amino acid sequence for said Group. This requirement is not to be construed as a requirement for an election of species, since each nucleotide and amino acid sequence is not a member of single genus of invention, but constitutes an independent and patentably distinct invention. The claims of the Group elected will be examined to the extent that they read on the elected sequence.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth F. McElwain whose telephone number is (703) 308-1794. The examiner can normally be reached on Monday through Friday from 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (703) 306-3218. The fax phone number for this Group is (703) 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

25

15

5

10

Serial No. 09/049,304 Art Unit 1638 -4-

Any inquiry of a general nature or relating to the status of this application should be directed to the legal analyst, Gwendolyn Payne, whose telephone number is (703) 305-2475, or to the Group receptionist whose telephone number is (703) 308-0196.

5 Elizabeth F. McElwain, Ph.D. April 5, 2002

PRIMARY EXAMINER
GROUP 1800

ESRAMEL